Merck to Present Latest Data from Innovative Cardiopulmonary Pipeline at AHA Scientific Sessions 2025

Rowe, New Jersey, USA2025Year10Month23Day——MSD (the corporate name of Merck & Co., Inc., located in Rahway, New Jersey, U.S.) announced that it will present the latest research findings from its cardiopulmonary pipeline and product portfolio at the American Heart Association (AHA) Scientific Sessions, to be held from November 7 to 10, 2025, in New Orleans, Louisiana, U.S. The research data showcased during this conference will further highlight MSD's unwavering commitment to driving innovation in areas such as hypercholesterolemia and pulmonary arterial hypertension (PAH), addressing the significant global burden posed by cardiopulmonary diseases.

The key data to be announced at that time will include:

Senior Vice President of Merck & Co., Inc. Laboratories, Head of Global Clinical Development for Integrated and Specialty CareJoerg KoglinDr. stated:"The AHA Annual Meeting Will Be a Significant Moment: Clinicians Will See for the First Time the Results of Two Pivotal Phase III Clinical Trials of Enlicitide and Understand the Potential of This Investigational Oral PCSK9 Inhibitor to Address the Significant Burden of Hypercholesterolemia After Approval. Cardiovascular Disease Remains the Leading Cause of Death Globally, with the Majority Being Atherosclerotic Cardiovascular Disease (ASCVD). MSD Is Committed to Advancing Innovation and Research, and Our Work in Reducing Low-Density Lipoprotein Cholesterol (LDL-C), One of the Major Modifiable Risk Factors for Atherosclerosis, Is an Important Part of the Company’s Efforts to Combat Cardiovascular Disease."

AHAInvestor Activities at the Scientific Annual Meeting:

      MSD will host an investor event at 6:00 PM CST on Sunday, November 9, 2025, in conjunction with the AHA Scientific Sessions, to share the company's strategy and project updates in the cardiopulmonary field. The event will take place in New Orleans, Louisiana, USA, and will be webcast live. Investors, analysts, media, and the public can access the event via the following:LinkWatch the speech live online. Participants can also dial in (Toll-free for the US and Canada: 800-369-2154; Other regions: 517-308-9422) and enter access code 6979269 to listen to the live broadcast.

AHAKey abstract data disclosed at the Scientific Annual Meeting include:

MSD's Commitment in the Cardiovascular Field

      MSD has a deep foundation and continuous innovation drive in the field of cardiovascular disease treatment. Since launching our first cardiovascular drug more than 70 years ago, we have remained committed to advancing scientific progress and exploring the nature of cardiovascular-related diseases. Cardiovascular disease remains one of the most serious health challenges of the 21st century and is the leading cause of death globally, claiming approximately 18 million lives each year.

      As an innovation leader in the industry, MSD consistently upholds scientific excellence throughout every phase of new drug research and development, regulatory approval, and lifecycle management. We actively collaborate with global experts in cardiovascular and pulmonary diseases to drive cutting-edge research forward, striving to deliver effective health solutions that truly improve the lives of patients worldwide.

About MSD

      At MSD (the corporate name of Merck & Co., Inc. in New Jersey, U.S.), we unite in pursuit of a shared mission: harnessing the power of leading-edge science to save and improve lives around the world. For over 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We are committed to being a top-tier research-intensive biopharmaceutical company — today, we stand at the forefront of research and development, delivering innovative solutions to advance the prevention and treatment of diseases in humans and animals. We have built a diverse and inclusive global workforce that operates responsibly every day, ensuring a safe, sustainable, and healthy future for all people and communities. For more information, visit www.msd.com and follow us on X (formerly Twitter), LinkedIn, and YouTube. 

About MSD China

      China is a crucial part of MSD's global growth strategy. MSD’s China headquarters is located in Shanghai, with a research and development center in Beijing and manufacturing facilities in Hangzhou, Ningbo, and Tianjin, integrating R&D, manufacturing, and commercial operations. We are fully committed to providing high-quality innovative medicines, vaccines, and services to the people of China, benefiting Chinese society. For more information, please visit MSD China's official website or follow MSD China's official social media accounts on WeChat. 

MSD Forward-Looking Statements

      MSD is the corporate name of Merck & Co., Inc., located in Rahway, New Jersey, USA (hereinafter referred to as "the Company"). This press release contains "forward-looking statements" made under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. The content herein is based on the current views and expectations of the Company’s management and is subject to significant risks and uncertainties. MSD does not guarantee that its products under development will receive the necessary regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate, or if risks or uncertainties arise, actual results may differ materially from those anticipated in the forward-looking statements.

      Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors (including interest rate and currency fluctuations), the impact of pharmaceutical industry regulations and healthcare policies in the United States and other countries, global trends toward healthcare cost containment, technological advances, new products and patents attained by competitors, inherent challenges in new product development (including obtaining regulatory approval), MSD's ability to accurately predict future market conditions, difficulties or delays in production, instability in international economic and financial conditions and sovereign risks, reliance on the effectiveness of MSD's patent and other innovative product protections, and the risk of patent litigation and/or regulatory actions against the company.

      MSD has no obligation to publicly update any forward-looking statements due to new information, future events, or other reasons. Other factors may cause actual results to differ materially from the forward-looking statements. For more information, please refer to MSD's 2024 Annual Report on Form 10-K and other documents filed with the U.S. Securities Exchange Commission (available at www.sec.gov).

[1]As of now, enlicitide decanoate has not been approved by the National Medical Products Administration (NMPA) of China.

[2]As of now, sotatercept-csrk has not been approved by the NMPA.